David W Dodick Selected Research

Headache (Headaches)

10/2022	Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache.
1/2022	FollowTheSutures: Piloting a new way to administer onabotulinumtoxinA for chronic migraine.
4/2021	Real-world efficacy, tolerability, and safety of ubrogepant.
1/2021	Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study.
1/2021	Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.
12/2020	Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis.
12/2020	The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine.
11/2020	Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study.
10/2020	The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response.
1/2020	Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David W Dodick Research Topics

Disease

143	Migraine Disorders (Migraine) 04/2022 - 01/2002
66	Headache (Headaches) 10/2022 - 06/2002
54	Pain (Aches) 10/2022 - 01/2002
15	Hyperalgesia 10/2022 - 03/2010
11	Nausea 01/2021 - 12/2008
9	Headache Disorders (Headache Syndromes) 10/2022 - 06/2002
9	Cluster Headache (Cluster Headaches) 09/2020 - 02/2008
8	Secondary Headache Disorders 01/2022 - 04/2006
7	Epilepsy (Aura) 01/2022 - 04/2006
7	Migraine with Aura (Familial Hemiplegic Migraine) 01/2022 - 10/2008
6	Primary Headache Disorders 09/2011 - 07/2003
5	Stroke (Strokes) 01/2022 - 04/2006
5	Traumatic Brain Injuries (Traumatic Brain Injury) 12/2021 - 07/2012
4	Prescription Drug Overuse 01/2021 - 04/2006
4	Ganglion Cysts (Ganglion) 09/2020 - 04/2017
4	Photophobia (Light Sensitivity) 07/2018 - 12/2008
4	Hyperacusis (Phonophobia) 07/2018 - 12/2008
4	Respiratory Tract Infections (Respiratory Tract Infection) 01/2018 - 02/2007
3	Post-Traumatic Headache 10/2022 - 01/2021
3	Sleepiness 12/2019 - 01/2004
3	Fatigue 11/2014 - 02/2007
3	Paresthesia (Dysesthesia) 03/2009 - 02/2007
2	Brain Concussion (Cerebral Concussion) 10/2022 - 01/2021
2	Migraine without Aura (Common Migraine) 01/2022 - 01/2022
2	Chronic Traumatic Encephalopathy 12/2021 - 01/2021
2	Hypertension (High Blood Pressure) 10/2021 - 01/2020
2	Dysgeusia (Parageusia) 01/2021 - 01/2020
2	Erythema 01/2020 - 09/2014
2	Ischemic Stroke 01/2020 - 09/2014
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 05/2004
2	Hypersensitivity (Allergy) 01/2015 - 03/2013
2	Mood Disorders (Mood Disorder) 02/2012 - 03/2003
2	Dizziness (Lightheadedness) 03/2009 - 01/2004
1	Chronic Pain 04/2022
1	Neuralgia (Stump Neuralgia) 04/2022
1	Nervous System Diseases (Neurological Disorders) 01/2022

Drug/Important Bio-Agent (IBA)

25	Tryptamines (Triptans)IBA 04/2022 - 03/2002
25	Calcitonin Gene-Related PeptideIBA 01/2022 - 12/2008
24	Type A Botulinum Toxins (Botox)FDA Link 10/2022 - 07/2003
18	Monoclonal AntibodiesIBA 01/2022 - 09/2014
15	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 04/2022 - 02/2011
14	Pharmaceutical PreparationsIBA 10/2022 - 09/2004
12	ubrogepantIBA 04/2022 - 08/2016
10	erenumabIBA 01/2022 - 04/2016
10	fremanezumabIBA 01/2021 - 11/2015
10	Analgesics (Analgesic Drugs)IBA 01/2020 - 03/2002
9	Sumatriptan (Imigran)FDA LinkGeneric 01/2022 - 01/2002
9	galcanezumabIBA 01/2021 - 09/2014
9	preemptIBA 12/2020 - 06/2010
9	zolmitriptan (Zomig)FDA Link 01/2019 - 01/2004
8	salicylhydroxamic acid (SHAM)IBA 01/2021 - 04/2006
8	Opioid Analgesics (Opioids)IBA 01/2021 - 04/2006
8	Pain-FreeIBA 01/2019 - 01/2002
7	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)IBA 10/2021 - 12/2008
7	Topiramate (Topamax)FDA LinkGeneric 04/2016 - 02/2007
5	eptinezumabIBA 01/2022 - 11/2014
5	Biological ProductsIBA 12/2021 - 07/2010
5	Indomethacin (Indometacin)FDA LinkGeneric 04/2010 - 06/2002
4	kappa Opioid Receptors (kappa Opioid Receptor)IBA 04/2022 - 05/2018
4	Biomarkers (Surrogate Marker)IBA 12/2021 - 07/2012
4	almotriptan (Axert)FDA Link 01/2007 - 01/2002
3	Dynorphins (Dynorphin)IBA 04/2022 - 05/2018
3	ProlactinIBA 01/2022 - 01/2020
3	(1R,5S)- 4- methyl- 1- propan- 2- ylbicyclo(3.1.0)hex- 3- en- 2- oneIBA 01/2022 - 12/2020
3	Adrenal Cortex Hormones (Corticosteroids)IBA 03/2013 - 08/2004
3	telcagepantIBA 02/2011 - 12/2008
3	eletriptan (Relpax)FDA Link 02/2008 - 02/2005
3	Serotonin (5 Hydroxytryptamine)IBA 01/2007 - 06/2003
3	incobotulinumtoxinA FDA Link 04/2005 - 04/2004
2	norbinaltorphimineIBA 04/2022 - 01/2021
2	LigandsIBA 04/2022 - 01/2019
2	atogepantIBA 01/2022 - 01/2020
2	AntibodiesIBA 01/2022 - 09/2014
2	Prolactin Receptors (Prolactin Receptor)IBA 01/2022 - 01/2020
2	TESIBA 12/2021 - 01/2021
2	Celecoxib (Celebrex)FDA Link 01/2021 - 01/2020
2	SolutionsIBA 01/2021 - 01/2020
2	Oral ContraceptivesIBA 01/2020 - 10/2008
2	Nitric Oxide DonorsIBA 01/2020 - 03/2010
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2020 - 09/2011
2	Morphine (MS Contin)FDA LinkGeneric 01/2019 - 05/2018
2	Capsaicin (Zostrix)FDA Link 01/2019 - 05/2018
2	Hormones (Hormone)IBA 09/2014 - 07/2010
2	BionIBA 09/2011 - 05/2009
2	Caffeine (No Doz)FDA LinkGeneric 05/2009 - 09/2007
2	naratriptan FDA LinkGeneric 01/2007 - 02/2005
2	rizatriptan (Maxalt)FDA Link 01/2007 - 02/2005
2	Botulinum Toxins (Botulinum Toxin)IBA 04/2004 - 07/2003
2	NeurotoxinsIBA 04/2004 - 07/2003
1	Dopamine Agonists (Dopamine Agonist)IBA 01/2022

Therapy/Procedure

47	Therapeutics 01/2022 - 03/2002
6	Injections 01/2022 - 07/2003
5	Transcranial Magnetic Stimulation 01/2022 - 04/2010
5	Aftercare (After-Treatment) 07/2019 - 11/2007
4	Subcutaneous Injections 01/2021 - 10/2017
3	Contraindications 01/2020 - 11/2012
2	Diffuse Noxious Inhibitory Control 01/2021 - 01/2019
2	Oral Administration 01/2020 - 06/2016
2	Deep Brain Stimulation 02/2009 - 02/2008
1	Ligation 04/2022